# Методы анализа

# Характеристика группы

## Демография + Анамнез

| **Characteristic** | **N = 118**1 |
| --- | --- |
| Age | 37 (30, 46) |
| Sex |  |
| female | 59 (50%) |
| male | 59 (50%) |
| Diagnosis |  |
| ALL | 34 (29%) |
| AML | 50 (42%) |
| CML | 4 (3.4%) |
| Lymphoma | 10 (8.5%) |
| MDS | 16 (14%) |
| myelofibrosis | 4 (3.4%) |
| BMT number |  |
| 1 | 110 (93%) |
| 2 | 5 (4.2%) |
| 3 | 3 (2.5%) |
| Disease status |  |
| CR | 104 (88%) |
| relapse | 14 (12%) |
| conditioning regime |  |
| MAC | 12 (10%) |
| RIC | 106 (90%) |
| failure type |  |
| Primary graft failure (+28 days) | 19 (34%) |
| Primary graft failure with restoration of own hematopoiesis (+28 day) | 4 (7.1%) |
| Primary graft hypofunction (2 shoots within 2 weeks) | 12 (21%) |
| Secondary graft failure (after engraftment) | 7 (13%) |
| Secondary graft hypofunction (2 shoots within 2 weeks) | 14 (25%) |
| Unknown | 62 |
| Отторжение |  |
| Да | 55 (47%) |
| Нет | 63 (53%) |
| Гипофункция трансплантата |  |
| Да | 23 (19%) |
| Нет | 95 (81%) |
| 1Median (IQR); n (%) | |

## КИРы

| **Characteristic** | **N = 118**1 |
| --- | --- |
| HLA-C1/С2 у больного: есть -1, нет-2 |  |
| 1 | 49 (42%) |
| 2 | 69 (58%) |
| GvH Direction по HLA - A03/11: есть - 1, нет - 2 |  |
| 1 | 16 (14%) |
| 2 | 102 (86%) |
| 2DL1 : есть -1, нет- 2 |  |
| 1 | 116 (98%) |
| 2 | 2 (1.7%) |
| HLA-C2/C2 у донора: есть-1, нет -2 |  |
| 1 | 22 (19%) |
| 2 | 96 (81%) |
| best -1, neutral/better-2 |  |
| 1 | 24 (20%) |
| 2 | 94 (80%) |
| 2DS3 больного: есть -1, нет- 2 |  |
| 1 | 43 (36%) |
| 2 | 75 (64%) |
| 2DL5 больного: 1 - есть, 2 - нет. |  |
| 1 | 65 (55%) |
| 2 | 53 (45%) |
| HvG Direction по HLA - A03/11: есть - 1, нет - 2. |  |
| 1 | 11 (9.3%) |
| 2 | 107 (91%) |
| Mismatching in the GvH Direction по HLA-C: есть-1, нет-2 |  |
| 1 | 27 (23%) |
| 2 | 91 (77%) |
| HLA-C2/C2 у больного: есть-1, нет -2 |  |
| 1 | 29 (25%) |
| 2 | 89 (75%) |
| Mismatching in the HvG Direction по HLA-B: есть-1, нет-2 |  |
| 1 | 16 (14%) |
| 2 | 102 (86%) |
| 2DS1 больного: есть -1, нет- 2 |  |
| 1 | 52 (44%) |
| 2 | 66 (56%) |
| Наличие А3 и А11 у донора: 1 - есть, 2 - нет. |  |
| 1 | 41 (35%) |
| 2 | 77 (65%) |
| HLA-C1/C1 у донора: есть-1, нет -2 |  |
| 1 | 39 (33%) |
| 2 | 79 (67%) |
| best/better -1, neutral-2 |  |
| 1 | 49 (42%) |
| 2 | 69 (58%) |
| KIR-генотип больного: B/B -1, другой - 2 |  |
| 1 | 30 (25%) |
| 2 | 88 (75%) |
| KIR-генотип больного: A/A-1, B/X-2 |  |
| 1 | 38 (32%) |
| 2 | 80 (68%) |
| 2DS2 больного: есть -1, нет- 2 |  |
| 1 | 53 (45%) |
| 2 | 65 (55%) |
| Mismatching in the GvH Direction по HLA-B: есть-1, нет-2 |  |
| 1 | 13 (11%) |
| 2 | 105 (89%) |
| 2DL2 : есть -1, нет- 2 |  |
| 1 | 63 (53%) |
| 2 | 55 (47%) |
| 2DS4f больного: есть - 1, нет - 2. |  |
| 1 | 22 (19%) |
| 2 | 96 (81%) |
| HLA-Bw4 у больного: есть -1, нет-2 |  |
| 1 | 93 (79%) |
| 2 | 25 (21%) |
| HLA-C1/C1 у больного: есть-1, нет -2 |  |
| 1 | 40 (34%) |
| 2 | 78 (66%) |
| бол. - нет лиг. донор для инг. KIR бол.: есть-1, нет-2 |  |
| 1 | 64 (54%) |
| 2 | 54 (46%) |
| 3DS1 больного: есть -1, нет- 2 |  |
| 1 | 48 (41%) |
| 2 | 70 (59%) |
| Число актив. KIR у больного |  |
| 1 | 36 (31%) |
| 2 | 18 (15%) |
| 3 | 11 (9.3%) |
| 4 | 29 (25%) |
| 5 | 16 (14%) |
| 6 | 7 (5.9%) |
| 8 | 1 (0.8%) |
| 2DS5 больного: есть -1, нет- 2 |  |
| 1 | 38 (32%) |
| 2 | 80 (68%) |
| Общее число KIR у больного |  |
| 7 | 36 (31%) |
| 8 | 5 (4.2%) |
| 9 | 15 (13%) |
| 10 | 7 (5.9%) |
| 11 | 24 (20%) |
| 12 | 16 (14%) |
| 13 | 6 (5.1%) |
| 14 | 8 (6.8%) |
| 15 | 1 (0.8%) |
| Число ингиб. KIR у больного |  |
| 5 | 2 (1.7%) |
| 6 | 43 (36%) |
| 7 | 46 (39%) |
| 8 | 24 (20%) |
| 9 | 3 (2.5%) |
| HLA-Bw4 у донора: есть -1, нет-2 |  |
| 1 | 93 (79%) |
| 2 | 25 (21%) |
| 2DL3: есть -1, нет- 2 |  |
| 1 | 94 (80%) |
| 2 | 24 (20%) |
| Mismatching in the HvG Direction по HLA-C: есть-1, нет-2 |  |
| 1 | 19 (16%) |
| 2 | 99 (84%) |
| 2DS4d больного: есть - 1, нет - 2. |  |
| 1 | 96 (81%) |
| 2 | 22 (19%) |
| HLA-C1/С2 у донора: есть -1, нет-2 |  |
| 1 | 57 (48%) |
| 2 | 61 (52%) |
| 1n (%) | |

# Сравнение по отторжению

## Демография + Анамнез

| **Characteristic** | **Да**, N = 551 | **Нет**, N = 631 | **p-value**2 |
| --- | --- | --- | --- |
| Age | 39 (33, 49) | 34 (29, 43) | 0.050 |
| Sex |  |  | 0.4 |
| female | 25 (45%) | 34 (54%) |  |
| male | 30 (55%) | 29 (46%) |  |
| Diagnosis |  |  | 0.3 |
| ALL | 15 (27%) | 19 (30%) |  |
| AML | 28 (51%) | 22 (35%) |  |
| CML | 1 (1.8%) | 3 (4.8%) |  |
| Lymphoma | 3 (5.5%) | 7 (11%) |  |
| MDS | 5 (9.1%) | 11 (17%) |  |
| myelofibrosis | 3 (5.5%) | 1 (1.6%) |  |
| BMT number |  |  | 0.5 |
| 1 | 53 (96%) | 57 (90%) |  |
| 2 | 1 (1.8%) | 4 (6.3%) |  |
| 3 | 1 (1.8%) | 2 (3.2%) |  |
| Disease status |  |  | 0.4 |
| CR | 50 (91%) | 54 (86%) |  |
| relapse | 5 (9.1%) | 9 (14%) |  |
| conditioning regime |  |  | 0.8 |
| MAC | 6 (11%) | 6 (9.5%) |  |
| RIC | 49 (89%) | 57 (90%) |  |
| failure type |  |  | 0.3 |
| Primary graft failure (+28 days) | 19 (36%) | 0 (0%) |  |
| Primary graft failure with restoration of own hematopoiesis (+28 day) | 4 (7.5%) | 0 (0%) |  |
| Primary graft hypofunction (2 shoots within 2 weeks) | 10 (19%) | 2 (67%) |  |
| Secondary graft failure (after engraftment) | 7 (13%) | 0 (0%) |  |
| Secondary graft hypofunction (2 shoots within 2 weeks) | 13 (25%) | 1 (33%) |  |
| Unknown | 2 | 60 |  |
| 1Median (IQR); n (%) | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test | | | |

## КИРы

| **Characteristic** | **Да**, N = 551 | **Нет**, N = 631 | **p-value**2 |
| --- | --- | --- | --- |
| HLA-C1/С2 у больного: есть -1, нет-2 |  |  | 0.8 |
| 1 | 22 (40%) | 27 (43%) |  |
| 2 | 33 (60%) | 36 (57%) |  |
| GvH Direction по HLA - A03/11: есть - 1, нет - 2 |  |  | 0.2 |
| 1 | 5 (9.1%) | 11 (17%) |  |
| 2 | 50 (91%) | 52 (83%) |  |
| 2DL1 : есть -1, нет- 2 |  |  | 0.5 |
| 1 | 55 (100%) | 61 (97%) |  |
| 2 | 0 (0%) | 2 (3.2%) |  |
| HLA-C2/C2 у донора: есть-1, нет -2 |  |  | >0.9 |
| 1 | 10 (18%) | 12 (19%) |  |
| 2 | 45 (82%) | 51 (81%) |  |
| best -1, neutral/better-2 |  |  | 0.4 |
| 1 | 13 (24%) | 11 (17%) |  |
| 2 | 42 (76%) | 52 (83%) |  |
| 2DS3 больного: есть -1, нет- 2 |  |  | >0.9 |
| 1 | 20 (36%) | 23 (37%) |  |
| 2 | 35 (64%) | 40 (63%) |  |
| 2DL5 больного: 1 - есть, 2 - нет. |  |  | 0.6 |
| 1 | 29 (53%) | 36 (57%) |  |
| 2 | 26 (47%) | 27 (43%) |  |
| HvG Direction по HLA - A03/11: есть - 1, нет - 2. |  |  | 0.6 |
| 1 | 6 (11%) | 5 (7.9%) |  |
| 2 | 49 (89%) | 58 (92%) |  |
| Mismatching in the GvH Direction по HLA-C: есть-1, нет-2 |  |  | 0.8 |
| 1 | 12 (22%) | 15 (24%) |  |
| 2 | 43 (78%) | 48 (76%) |  |
| HLA-C2/C2 у больного: есть-1, нет -2 |  |  | 0.8 |
| 1 | 13 (24%) | 16 (25%) |  |
| 2 | 42 (76%) | 47 (75%) |  |
| Mismatching in the HvG Direction по HLA-B: есть-1, нет-2 |  |  | 0.8 |
| 1 | 7 (13%) | 9 (14%) |  |
| 2 | 48 (87%) | 54 (86%) |  |
| 2DS1 больного: есть -1, нет- 2 |  |  | 0.6 |
| 1 | 23 (42%) | 29 (46%) |  |
| 2 | 32 (58%) | 34 (54%) |  |
| Наличие А3 и А11 у донора: 1 - есть, 2 - нет. |  |  | >0.9 |
| 1 | 19 (35%) | 22 (35%) |  |
| 2 | 36 (65%) | 41 (65%) |  |
| HLA-C1/C1 у донора: есть-1, нет -2 |  |  | 0.6 |
| 1 | 17 (31%) | 22 (35%) |  |
| 2 | 38 (69%) | 41 (65%) |  |
| best/better -1, neutral-2 |  |  | 0.5 |
| 1 | 21 (38%) | 28 (44%) |  |
| 2 | 34 (62%) | 35 (56%) |  |
| KIR-генотип больного: B/B -1, другой - 2 |  |  | 0.4 |
| 1 | 16 (29%) | 14 (22%) |  |
| 2 | 39 (71%) | 49 (78%) |  |
| KIR-генотип больного: A/A-1, B/X-2 |  |  | 0.8 |
| 1 | 17 (31%) | 21 (33%) |  |
| 2 | 38 (69%) | 42 (67%) |  |
| 2DS2 больного: есть -1, нет- 2 |  |  | 0.3 |
| 1 | 22 (40%) | 31 (49%) |  |
| 2 | 33 (60%) | 32 (51%) |  |
| Mismatching in the GvH Direction по HLA-B: есть-1, нет-2 |  |  | >0.9 |
| 1 | 6 (11%) | 7 (11%) |  |
| 2 | 49 (89%) | 56 (89%) |  |
| 2DL2 : есть -1, нет- 2 |  |  | 0.6 |
| 1 | 28 (51%) | 35 (56%) |  |
| 2 | 27 (49%) | 28 (44%) |  |
| 2DS4f больного: есть - 1, нет - 2. |  |  | 0.3 |
| 1 | 8 (15%) | 14 (22%) |  |
| 2 | 47 (85%) | 49 (78%) |  |
| HLA-Bw4 у больного: есть -1, нет-2 |  |  | 0.5 |
| 1 | 42 (76%) | 51 (81%) |  |
| 2 | 13 (24%) | 12 (19%) |  |
| HLA-C1/C1 у больного: есть-1, нет -2 |  |  | 0.6 |
| 1 | 20 (36%) | 20 (32%) |  |
| 2 | 35 (64%) | 43 (68%) |  |
| бол. - нет лиг. донор для инг. KIR бол.: есть-1, нет-2 |  |  | 0.8 |
| 1 | 29 (53%) | 35 (56%) |  |
| 2 | 26 (47%) | 28 (44%) |  |
| 3DS1 больного: есть -1, нет- 2 |  |  | 0.2 |
| 1 | 19 (35%) | 29 (46%) |  |
| 2 | 36 (65%) | 34 (54%) |  |
| Число актив. KIR у больного |  |  | 0.6 |
| 1 | 15 (27%) | 21 (33%) |  |
| 2 | 11 (20%) | 7 (11%) |  |
| 3 | 7 (13%) | 4 (6.3%) |  |
| 4 | 13 (24%) | 16 (25%) |  |
| 5 | 7 (13%) | 9 (14%) |  |
| 6 | 2 (3.6%) | 5 (7.9%) |  |
| 8 | 0 (0%) | 1 (1.6%) |  |
| 2DS5 больного: есть -1, нет- 2 |  |  | 0.5 |
| 1 | 16 (29%) | 22 (35%) |  |
| 2 | 39 (71%) | 41 (65%) |  |
| Общее число KIR у больного |  |  | 0.4 |
| 7 | 15 (27%) | 21 (33%) |  |
| 8 | 3 (5.5%) | 2 (3.2%) |  |
| 9 | 9 (16%) | 6 (9.5%) |  |
| 10 | 4 (7.3%) | 3 (4.8%) |  |
| 11 | 12 (22%) | 12 (19%) |  |
| 12 | 8 (15%) | 8 (13%) |  |
| 13 | 0 (0%) | 6 (9.5%) |  |
| 14 | 4 (7.3%) | 4 (6.3%) |  |
| 15 | 0 (0%) | 1 (1.6%) |  |
| Число ингиб. KIR у больного |  |  | 0.3 |
| 5 | 0 (0%) | 2 (3.2%) |  |
| 6 | 20 (36%) | 23 (37%) |  |
| 7 | 25 (45%) | 21 (33%) |  |
| 8 | 8 (15%) | 16 (25%) |  |
| 9 | 2 (3.6%) | 1 (1.6%) |  |
| HLA-Bw4 у донора: есть -1, нет-2 |  |  | 0.3 |
| 1 | 41 (75%) | 52 (83%) |  |
| 2 | 14 (25%) | 11 (17%) |  |
| 2DL3: есть -1, нет- 2 |  |  | 0.4 |
| 1 | 42 (76%) | 52 (83%) |  |
| 2 | 13 (24%) | 11 (17%) |  |
| Mismatching in the HvG Direction по HLA-C: есть-1, нет-2 |  |  | 0.2 |
| 1 | 6 (11%) | 13 (21%) |  |
| 2 | 49 (89%) | 50 (79%) |  |
| 2DS4d больного: есть - 1, нет - 2. |  |  | 0.3 |
| 1 | 47 (85%) | 49 (78%) |  |
| 2 | 8 (15%) | 14 (22%) |  |
| HLA-C1/С2 у донора: есть -1, нет-2 |  |  | 0.6 |
| 1 | 28 (51%) | 29 (46%) |  |
| 2 | 27 (49%) | 34 (54%) |  |
| 1n (%) | | | |
| 2Pearson's Chi-squared test; Fisher's exact test | | | |

# Cравнение по гипофункции

## Демография + Анамнез

| **Characteristic** | **Да**, N = 231 | **Нет**, N = 951 | **p-value**2 |
| --- | --- | --- | --- |
| Age | 39 (31, 43) | 36 (30, 47) | 0.9 |
| Sex |  |  | 0.8 |
| female | 11 (48%) | 48 (51%) |  |
| male | 12 (52%) | 47 (49%) |  |
| Diagnosis |  |  | 0.7 |
| ALL | 7 (30%) | 27 (28%) |  |
| AML | 11 (48%) | 39 (41%) |  |
| CML | 1 (4.3%) | 3 (3.2%) |  |
| Lymphoma | 0 (0%) | 10 (11%) |  |
| MDS | 3 (13%) | 13 (14%) |  |
| myelofibrosis | 1 (4.3%) | 3 (3.2%) |  |
| BMT number |  |  | 0.8 |
| 1 | 23 (100%) | 87 (92%) |  |
| 2 | 0 (0%) | 5 (5.3%) |  |
| 3 | 0 (0%) | 3 (3.2%) |  |
| Disease status |  |  | >0.9 |
| CR | 20 (87%) | 84 (88%) |  |
| relapse | 3 (13%) | 11 (12%) |  |
| conditioning regime |  |  | 0.7 |
| MAC | 3 (13%) | 9 (9.5%) |  |
| RIC | 20 (87%) | 86 (91%) |  |
| failure type |  |  | <0.001 |
| Primary graft failure (+28 days) | 0 (0%) | 19 (58%) |  |
| Primary graft failure with restoration of own hematopoiesis (+28 day) | 0 (0%) | 4 (12%) |  |
| Primary graft hypofunction (2 shoots within 2 weeks) | 11 (48%) | 1 (3.0%) |  |
| Secondary graft failure (after engraftment) | 1 (4.3%) | 6 (18%) |  |
| Secondary graft hypofunction (2 shoots within 2 weeks) | 11 (48%) | 3 (9.1%) |  |
| Unknown | 0 | 62 |  |
| 1Median (IQR); n (%) | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test | | | |

## КИРы

| **Characteristic** | **Да**, N = 231 | **Нет**, N = 951 | **p-value**2 |
| --- | --- | --- | --- |
| HLA-C1/С2 у больного: есть -1, нет-2 |  |  | 0.2 |
| 1 | 7 (30%) | 42 (44%) |  |
| 2 | 16 (70%) | 53 (56%) |  |
| GvH Direction по HLA - A03/11: есть - 1, нет - 2 |  |  | 0.2 |
| 1 | 1 (4.3%) | 15 (16%) |  |
| 2 | 22 (96%) | 80 (84%) |  |
| 2DL1 : есть -1, нет- 2 |  |  | >0.9 |
| 1 | 23 (100%) | 93 (98%) |  |
| 2 | 0 (0%) | 2 (2.1%) |  |
| HLA-C2/C2 у донора: есть-1, нет -2 |  |  | 0.6 |
| 1 | 3 (13%) | 19 (20%) |  |
| 2 | 20 (87%) | 76 (80%) |  |
| best -1, neutral/better-2 |  |  | 0.6 |
| 1 | 6 (26%) | 18 (19%) |  |
| 2 | 17 (74%) | 77 (81%) |  |
| 2DS3 больного: есть -1, нет- 2 |  |  | 0.5 |
| 1 | 7 (30%) | 36 (38%) |  |
| 2 | 16 (70%) | 59 (62%) |  |
| 2DL5 больного: 1 - есть, 2 - нет. |  |  | 0.4 |
| 1 | 11 (48%) | 54 (57%) |  |
| 2 | 12 (52%) | 41 (43%) |  |
| HvG Direction по HLA - A03/11: есть - 1, нет - 2. |  |  | 0.4 |
| 1 | 3 (13%) | 8 (8.4%) |  |
| 2 | 20 (87%) | 87 (92%) |  |
| Mismatching in the GvH Direction по HLA-C: есть-1, нет-2 |  |  | 0.13 |
| 1 | 8 (35%) | 19 (20%) |  |
| 2 | 15 (65%) | 76 (80%) |  |
| HLA-C2/C2 у больного: есть-1, нет -2 |  |  | 0.9 |
| 1 | 6 (26%) | 23 (24%) |  |
| 2 | 17 (74%) | 72 (76%) |  |
| Mismatching in the HvG Direction по HLA-B: есть-1, нет-2 |  |  | 0.7 |
| 1 | 2 (8.7%) | 14 (15%) |  |
| 2 | 21 (91%) | 81 (85%) |  |
| 2DS1 больного: есть -1, нет- 2 |  |  | 0.3 |
| 1 | 8 (35%) | 44 (46%) |  |
| 2 | 15 (65%) | 51 (54%) |  |
| Наличие А3 и А11 у донора: 1 - есть, 2 - нет. |  |  | 0.14 |
| 1 | 5 (22%) | 36 (38%) |  |
| 2 | 18 (78%) | 59 (62%) |  |
| HLA-C1/C1 у донора: есть-1, нет -2 |  |  | 0.5 |
| 1 | 9 (39%) | 30 (32%) |  |
| 2 | 14 (61%) | 65 (68%) |  |
| best/better -1, neutral-2 |  |  | 0.8 |
| 1 | 10 (43%) | 39 (41%) |  |
| 2 | 13 (57%) | 56 (59%) |  |
| KIR-генотип больного: B/B -1, другой - 2 |  |  | 0.3 |
| 1 | 8 (35%) | 22 (23%) |  |
| 2 | 15 (65%) | 73 (77%) |  |
| KIR-генотип больного: A/A-1, B/X-2 |  |  | 0.4 |
| 1 | 9 (39%) | 29 (31%) |  |
| 2 | 14 (61%) | 66 (69%) |  |
| 2DS2 больного: есть -1, нет- 2 |  |  | 0.5 |
| 1 | 9 (39%) | 44 (46%) |  |
| 2 | 14 (61%) | 51 (54%) |  |
| Mismatching in the GvH Direction по HLA-B: есть-1, нет-2 |  |  | 0.7 |
| 1 | 3 (13%) | 10 (11%) |  |
| 2 | 20 (87%) | 85 (89%) |  |
| 2DL2 : есть -1, нет- 2 |  |  | 0.9 |
| 1 | 12 (52%) | 51 (54%) |  |
| 2 | 11 (48%) | 44 (46%) |  |
| 2DS4f больного: есть - 1, нет - 2. |  |  | >0.9 |
| 1 | 4 (17%) | 18 (19%) |  |
| 2 | 19 (83%) | 77 (81%) |  |
| HLA-Bw4 у больного: есть -1, нет-2 |  |  | >0.9 |
| 1 | 18 (78%) | 75 (79%) |  |
| 2 | 5 (22%) | 20 (21%) |  |
| HLA-C1/C1 у больного: есть-1, нет -2 |  |  | 0.3 |
| 1 | 10 (43%) | 30 (32%) |  |
| 2 | 13 (57%) | 65 (68%) |  |
| бол. - нет лиг. донор для инг. KIR бол.: есть-1, нет-2 |  |  | 0.8 |
| 1 | 12 (52%) | 52 (55%) |  |
| 2 | 11 (48%) | 43 (45%) |  |
| 3DS1 больного: есть -1, нет- 2 |  |  | 0.039 |
| 1 | 5 (22%) | 43 (45%) |  |
| 2 | 18 (78%) | 52 (55%) |  |
| Число актив. KIR у больного |  |  | 0.6 |
| 1 | 8 (35%) | 28 (29%) |  |
| 2 | 6 (26%) | 12 (13%) |  |
| 3 | 2 (8.7%) | 9 (9.5%) |  |
| 4 | 5 (22%) | 24 (25%) |  |
| 5 | 1 (4.3%) | 15 (16%) |  |
| 6 | 1 (4.3%) | 6 (6.3%) |  |
| 8 | 0 (0%) | 1 (1.1%) |  |
| 2DS5 больного: есть -1, нет- 2 |  |  | 0.8 |
| 1 | 7 (30%) | 31 (33%) |  |
| 2 | 16 (70%) | 64 (67%) |  |
| Общее число KIR у больного |  |  | 0.5 |
| 7 | 8 (35%) | 28 (29%) |  |
| 8 | 1 (4.3%) | 4 (4.2%) |  |
| 9 | 6 (26%) | 9 (9.5%) |  |
| 10 | 0 (0%) | 7 (7.4%) |  |
| 11 | 4 (17%) | 20 (21%) |  |
| 12 | 3 (13%) | 13 (14%) |  |
| 13 | 0 (0%) | 6 (6.3%) |  |
| 14 | 1 (4.3%) | 7 (7.4%) |  |
| 15 | 0 (0%) | 1 (1.1%) |  |
| Число ингиб. KIR у больного |  |  | 0.8 |
| 5 | 0 (0%) | 2 (2.1%) |  |
| 6 | 10 (43%) | 33 (35%) |  |
| 7 | 10 (43%) | 36 (38%) |  |
| 8 | 3 (13%) | 21 (22%) |  |
| 9 | 0 (0%) | 3 (3.2%) |  |
| HLA-Bw4 у донора: есть -1, нет-2 |  |  | 0.8 |
| 1 | 19 (83%) | 74 (78%) |  |
| 2 | 4 (17%) | 21 (22%) |  |
| 2DL3: есть -1, нет- 2 |  |  | 0.6 |
| 1 | 17 (74%) | 77 (81%) |  |
| 2 | 6 (26%) | 18 (19%) |  |
| Mismatching in the HvG Direction по HLA-C: есть-1, нет-2 |  |  | >0.9 |
| 1 | 4 (17%) | 15 (16%) |  |
| 2 | 19 (83%) | 80 (84%) |  |
| 2DS4d больного: есть - 1, нет - 2. |  |  | 0.8 |
| 1 | 18 (78%) | 78 (82%) |  |
| 2 | 5 (22%) | 17 (18%) |  |
| HLA-C1/С2 у донора: есть -1, нет-2 |  |  | >0.9 |
| 1 | 11 (48%) | 46 (48%) |  |
| 2 | 12 (52%) | 49 (52%) |  |
| 1n (%) | | | |
| 2Pearson's Chi-squared test; Fisher's exact test | | | |